使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to the ICN Pharmaceuticals second quarter 2003 earnings results conference call. (CALLER INSTRUCTIONS). At this time for opening remarks and introductions, I would now like to turn the conference over to Ms. Eileen Pruette, General Counsel of ICN. Please go-ahead.
歡迎參加 ICN Pharmaceuticals 2003 年第二季財報結果電話會議。(來電者指示)現在進行開場致詞與介紹,我想把會議交給 ICN 法務長 Eileen Pruette 女士。請開始。
Eileen Pruette - EVP and General Counsel
Eileen Pruette - EVP and General Counsel
Good morning and welcome everyone to today's call. Before we begin the call, I would like to call your attention to the fact that this presentation may contain forward-looking statements that may involve risks and uncertainties including but not limited to projections of future sales, royalty income, operating income, regulatory approval processes, litigation related to and competition from generic products, success of efforts to develop, acquire and market new products and to refocus marketing of existing products, marketplace acceptance of the Company's products, success of the Company's strategic repositioning initiatives and the ability of management to execute them, cost-cutting measures and other risks detailed from time to time in the Company's Securities and Exchange Commission filings. In addition, certain information related to this presentation is furnished in the investor relation's section of the Company's Web site at www.icnpharm.com pursuant to the rules and regulations of the Securities and Exchange Commission.
各位早安,歡迎大家參加今天的電話會議。在我們開始之前,我想提醒各位,本簡報可能包含前瞻性陳述,可能涉及風險與不確定性,包括但不限於:未來銷售、權利金收入、營業利益之預測;法規核准流程;與學名藥產品相關之訴訟及其競爭;開發、取得與行銷新產品,以及重新聚焦既有產品行銷之努力是否成功;市場對本公司產品之接受度;本公司策略性重新定位計畫之成功與管理階層執行能力;成本削減措施;以及本公司不時於向美國證券交易委員會(SEC)申報文件中所詳述之其他風險。此外,與本簡報相關之部分資訊,依據 SEC 之規則與規定,已提供於本公司網站 www.icnpharm.com 的投資人關係專區。
On the call today are Robert W. O'Leary, ICN's Chairman and Chief Executive Officer, Timothy C. Tyson, President and Chief Operating Officer and Bary G. Bailey, Chief Financial Officer. Wes Wheeler, President North America, Willi Wu, Controller, and Phil Loburg, Treasurer, are also here and available to answer questions during the Q&A session.
今天參與電話會議的有 ICN 董事長兼執行長 Robert W. O'Leary、總裁兼營運長 Timothy C. Tyson,以及財務長 Bary G. Bailey。北美總裁 Wes Wheeler、會計主管(Controller)Willi Wu 與財務主管(Treasurer)Phil Loburg 也在現場,並將於問答環節提供回答。
Now I would like to turn the call over to Mr. O'Leary. Rob?
現在我想把電話會議交給 O'Leary 先生。Rob?
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
Thank you Eileen. Good morning everyone. Thank you for joining us on today's call. This morning, we announced our second quarter results for 2003. Revenues from continuing operations in the second quarter were 183.5 million, slightly ahead of the second quarter last year. Revenues include strong performance from our specialty pharmaceutical business in which product sales are up 15 percent over the second quarter last year Partially offset by 21 percent decline in royalty revenues at Ribopharm. Income from continuing operations in the second quarter totaled 17.4 million or 21 cents per diluted share compared with 21.9 million or 31 cents per diluted share in the second quarter last year after you exclude the nonrecurring and unusual items that were booked last year.
謝謝你,Eileen。各位早安。感謝各位參加今天的電話會議。今天早上,我們公布了 2003 年第二季的業績結果。第二季持續營運之營收為 1.835 億,略高於去年第二季。營收包含我們專科製藥業務的強勁表現,該業務產品銷售較去年第二季成長 15%,但部分被 Ribopharm 權利金收入下滑 21% 所抵銷。第二季持續營運之淨利合計 1,740 萬美元,或稀釋後每股 0.21 美元;相較之下,去年第二季在排除去年入帳的一次性與非經常性項目後,為 2,190 萬美元,或稀釋後每股 0.31 美元。
Second quarter results also show strong improvement over the first quarter of this year. It demonstrates our continued strategic execution with momentum building in our core business. Revenues in the second quarter were up 19 percent over the first quarter this year while income from continuing operations was nearly 30 percent higher than the previous quarter.
第二季結果也顯示相較於今年第一季有顯著改善。這展現我們持續落實策略執行,核心業務動能正在累積。第二季營收較今年第一季成長 19%,而持續營運之淨利則較前一季提高近 30%。
Bary, Mr. Bailey, will walk through the detailed financial results with you in a few minutes. I'd like to give you an overall perspective on the quarter however and point out the factors that drove our performance.
Bary,也就是 Bailey 先生,將在幾分鐘後帶各位檢視更詳細的財務結果。不過我想先就本季提供整體觀點,並指出推動我們表現的因素。
Consistent with our strategic direction announced in November last year, we are pleased to report our renewed focus on our specialty pharmaceutical business has begun to bear fruit. Specialty pharmaceuticals performed remarkably well this quarter, better than our own expectations and decidedly ahead of last year. The improvement in this business was primarily driven by strong performance in North America and Europe both of which came in well ahead of expectations and the prior year.
依循我們去年 11 月宣布的策略方向,我們很高興報告,重新聚焦於專科製藥業務已開始開花結果。本季專科製藥表現非常出色,優於我們自身預期,且明顯領先去年。此業務的改善主要由北美與歐洲的強勁表現所帶動,兩者皆大幅優於預期與去年同期。
Our emphasis on North America, the world's largest pharmaceutical market, is bearing fruit as well. With the impact of wholesale inventories in the US behind us behind us and with solid performance by our leading products, our North American business turned in a very strong quarter and is beginning to build momentum that augers well for the future.
我們對北美—全球最大的製藥市場—的重點投入也正在見效。隨著美國批發通路庫存的影響已經過去,且我們主力產品表現穩健,我們北美業務交出非常強勁的一季,並開始累積動能,對未來前景是個好兆頭。
Although sales in Latin America were slightly ahead of last year, our business is facing challenges due to economic pressures and reduced government funding. Tim, Mr. Tyson, will tell you more about how we're dealing with these issues by wrapping up our sales force and redirecting our sales efforts toward retail pharmacies, which are becoming an important focus of sales in Mexico. Tim will talk about each of our regions in more detail shortly, including an update of progress on our strategic plans.
雖然拉丁美洲的銷售略高於去年,但由於經濟壓力與政府資金縮減,我們的業務正面臨挑戰。Tim,也就是 Tyson 先生,將進一步說明我們如何透過精簡銷售團隊並將銷售重心轉向零售藥局來因應這些問題;零售藥局正成為墨西哥銷售的重要焦點。Tim 稍後也會更詳細談各區域的情況,包括我們策略計畫進展的最新更新。
Our Ribopharm operations experienced the greatest challenge this quarter. As you know Ribopharm operations are driven by royalties from the sale of ribavirin by Schering-Plough and Roche. As ribavirin shared with you in the second quarter results this past week, royalty revenues were down more than 20 percent from the second quarter last year. I know that many of you follow ribavirin very closely and are well aware of the challenges reported by Shering with respect to market competition from Roche and trade inventory levels in the US since early this year. These challenges certainly did not go away in the second quarter. In addition the recent lower cost summary judgment ruling in our patent litigation in favor of the generic manufacturers has cast a cloud over branded ribavirin sales in the United States for the remainder of this year.
本季 Ribopharm 營運遭遇最大的挑戰。如各位所知,Ribopharm 的營運主要由 Schering-Plough 與 Roche 銷售 ribavirin 所產生的權利金所驅動。正如我們在本週公布的第二季結果中與各位分享的,權利金收入較去年第二季下滑超過 20%。我知道各位當中許多人密切關注 ribavirin,也很清楚 Schering 所提到的挑戰,包括來自 Roche 的市場競爭,以及自今年初以來美國通路貿易庫存水位的影響。這些挑戰在第二季當然沒有消失。此外,近期在我們專利訴訟中,法院就較低成本的簡易判決(summary judgment)裁定支持學名藥製造商,亦使今年剩餘期間美國品牌 ribavirin 的銷售蒙上一層陰影。
Because of this decision, we believe that Shering and Roche will face generic competition in the US much sooner than some may have expected. This could have a significant impact on Ribopharm royalty revenues in 2003 and of course our bottom-line. The confluence of these recent events has created an environment that makes it difficult for us to have any visibility into future ribavirin sales at this time. Plus, it's problematic to make any projections of Ribopharm's royalty revenues.
由於此一裁定,我們認為 Schering 與 Roche 在美國面臨學名藥競爭的時間,將比部分人士原先預期更早。這可能對 2003 年 Ribopharm 的權利金收入,當然也對我們的最終獲利,造成重大影響。近期事件的交互影響,造成目前我們難以掌握未來 ribavirin 銷售的能見度。此外,也使得對 Ribopharm 權利金收入做任何預測都變得相當棘手。
In spite of this challenge, we're driving the Company toward profitable business model that will not depend on royalty revenue for future growth while managing our business toward long-term growth and shareholder value. We believe our efforts are already being realized in the stronger and more sustainable performance this quarter from the specialty pharmaceutical business and we are just beginning.
儘管面臨此一挑戰,我們仍在推動公司朝向更具獲利性的商業模式前進,未來成長將不再依賴權利金收入,同時也以長期成長與股東價值為目標來管理我們的業務。我們相信,我們的努力已在本季專科製藥業務更強勁且更可持續的表現中開始展現成果,而這才剛開始。
As Tim will indicate, we're finalizing the strategic plans we have been talking about all year that will dramatically increase efficiency in our operations and also, drive top-line growth in our business.
正如 Tim 將指出的,我們正在定案今年以來一直在討論的策略計畫,該計畫將大幅提升營運效率,同時也將帶動我們業務的營收成長。
It's important to note to you that the new management team, Tim and Wes, have been here nearly six months and we are on the cusp of announcing some significant improvements, we believe, in our operations that will dramatically improve things for the future. While it's perhaps a little premature to share the specifics of those details with you now, Tim will give you additional texture about where we are going and we do expect to be making major announcements in the not too distant future about those efficiencies now moving forward very aggressively and expect to have more to share with you in the near future.
需要向各位強調的是,新管理團隊 Tim 與 Wes 到任已將近六個月,我們正處於即將宣布一些重大改善的關鍵時點;我們相信,這些改善將在未來大幅提升我們的營運表現。雖然現在分享具體細節可能還稍嫌過早,但 Tim 會提供更多我們前進方向的脈絡;我們也預期在不久的將來,會就這些效率提升做出重大公告。我們正非常積極地推進,並預期近期能與各位分享更多。
With that, I will turn the call over to Tim for a review of the specialty pharmaceutical operations.
接下來,我把電話會議交給 Tim,請他回顧專科製藥業務的營運情況。
Tim Tyson - President and COO
Tim Tyson - President and COO
Thank you Rob and welcome everyone. As Rob indicated, our specialty pharmaceuticals business this quarter turned in a very strong performance growing 15 percent growth compared to the same time last year. This performance was driven largely by North America and Europe. Latin America sales were up slightly compared to last year but as Rob mentioned, faced some challenges this quarter. I will spend a few minutes talking about regional performance, highlight product contributions and specific initiatives that are already underway.
謝謝你,Rob,也歡迎各位。如 Rob 所指出,我們本季專科製藥業務表現非常強勁,較去年同期成長 15%。這項表現主要由北美與歐洲所帶動。拉丁美洲銷售較去年略有成長,但如 Rob 所提,本季也面臨一些挑戰。我將花幾分鐘談談各區域的表現,重點說明產品貢獻,以及目前已在進行中的具體措施。
We are very encouraged by the improvements in our North American operations. We consider North America to be our most important market opportunity. It represents about 50 percent of the overall worldwide pharmaceutical market. Yet, North American sales for ICN in the past have only represented about 20 to 25 percent of our overall sales. We view the potential upside opportunity in this market to be significant.
我們對北美營運的改善感到非常振奮。我們認為北美是我們最重要的市場機會。北美約占全球整體製藥市場的 50%。然而,過去 ICN 在北美的銷售僅約占我們總銷售的 20% 至 25%。我們認為此市場的上行潛力相當可觀。
Our decision to concentrate more effort in this important market is already paying off. North American product sales of $26.1 million this quarter increased 34 percent over the same period last year and 70.6 percent over the first quarter of this year and operating income increased 89 percent in the second quarter to $9 million compared to the same period last year. This significant improvement was driven by several factors.
我們決定在這個重要市場投入更多心力,已經開始見到成效。本季北美產品銷售額為2,610萬美元,較去年同期成長34%,較今年第一季成長70.6%;第二季營業利益較去年同期大增89%,達900萬美元。這項顯著改善是由多項因素所帶動。
Firstly, as we indicated last quarter, our wholesale inventory efforts in the United States were completed in April, two months ahead of schedule. Our second quarter therefore, includes about two months of sales that more closely reflect retail demand, whereas last year at this time, we were just beginning these inventory reduction measures. We continue to carefully monitor wholesale buying patterns to assure that wholesale inventories remain properly aligned with retail sales.
首先,如同我們上季所指出的,我們在美國的批發庫存調整工作已於4月完成,比原定時程提前兩個月。因此,我們第二季包含約兩個月更能反映零售需求的銷售;而去年此時我們才剛開始進行這些去化庫存措施。我們將持續審慎監控批發採購模式,以確保批發庫存與零售銷售維持適當一致。
Secondly, our new promotional efforts and focus have resulted in stabilization and growth of our core dermatological products in North America specifically, Efudex and more recently Kinerase. Efudex continues as the actinic keratoses market leader with a 51 percent market share in the United States. In spite of a new competitive product introduction, Efudex has recaptured about 2 percent market share since the fourth quarter 2002 for IMS data. Kinerase, an antiaging cosmeceutical, has shown significant growth in the past several weeks following a revised focus and extensive media coverage. We recently resized and restructured our U.S. sales force to increase reach and frequency in the specialist community and expect sales of our dermatology products to contribute to future growth. Our recent re-launch of Oxsoralen, an effective puba (ph) treatment for severe psoriasis, will also contribute to future growth.
其次,我們新的促銷作為與聚焦策略,使我們在北美的核心皮膚科產品(特別是Efudex,以及較近期的Kinerase)得以穩定並成長。Efudex仍為美國日光性角化症市場的領導品牌,市占率達51%。儘管有新的競品上市,根據IMS資料,Efudex自2002年第四季以來已回升約2%的市占率。Kinerase作為抗老化的醫學美容產品(cosmeceutical),在重新聚焦並獲得大量媒體報導後,過去數週呈現顯著成長。我們近期已調整並重整美國銷售團隊規模與架構,以提升在專科社群的覆蓋與拜訪頻率,並預期皮膚科產品銷售將帶動未來成長。我們近期重新上市的Oxsoralen(用於嚴重乾癬的有效puba(ph)治療)也將有助於未來成長。
Mestinon, our leading global brand and product for the treatment of myasthenia gravis continues to be a strong global product. Our generic defense strategy in the United States, implemented in January 2003, has been highly effective at retaining business, about 15 percent above typical generic erosion models. Sales of Librax, a product used in gastrointestinal pain and cesamet, a synthetic cannaboid sold in Canada, also showed strong performance this quarter.
Mestinon作為我們全球領先品牌、用於治療重症肌無力的產品,仍持續展現強勁的全球表現。我們於2003年1月在美國推行的學名藥防禦策略,在維持業務方面成效顯著,較典型的學名藥侵蝕模型高出約15%。Librax(用於腸胃道疼痛)以及在加拿大銷售的Cesamet(合成大麻素)本季亦表現強勁。
Finally, a focus on managing expenses and gross margin while investing in appropriate promotional activities has resulted in the 89 percent improvement in operating income previously mentioned.
最後,在投入適當促銷活動的同時,聚焦於費用與毛利率管理,促成前述營業利益提升89%。
European product sales of 59.3 million were also well ahead, increasing 20 percent. Operating income in Europe of $9.3 million was 59 percent ahead of last year. Europe's strong results were primarily driven by sales of products in the infectious disease and specialty neurology categories. Major contributors were Virazole, Ancotil and Mestinon.
歐洲產品銷售額為5,930萬美元,同樣大幅超前,成長20%。歐洲營業利益為930萬美元,較去年成長59%。歐洲的強勁成果主要由感染性疾病與專科神經科類別產品的銷售所帶動。主要貢獻者為Virazole、Ancotil與Mestinon。
Virazole was approved in Russia for the treatment of HFRS, a viral disease, and has seen significant use in the treatment of RSV and other adenyl (ph) viruses. Mestinon performed well as a result of strong promotion in conjunction with the Myasthenia Gravis Association.
Virazole已在俄羅斯獲准用於治療HFRS(一種病毒性疾病),並在治療RSV及其他腺yl(ph)病毒方面有顯著使用量。Mestinon在與重症肌無力協會合作進行強力推廣下,表現良好。
Dermatix, a new product for the treatment and management of scars, has been launched in Germany, the United Kingdom, Austria, Switzerland, Spain and Holland. Initial market feedback has been very favorable. This product will be launched in a number of additional markets in the coming months.
Dermatix是一項用於疤痕治療與管理的新產品,已在德國、英國、奧地利、瑞士、西班牙與荷蘭上市。初期市場回饋非常正面。未來數月內,該產品將在更多市場推出。
These impressive results were achieved in spite of tremendous challenges with German health care reform, reference-pricing legislation in Spain and Italian price control.
儘管面臨德國醫療改革、西班牙參考定價立法以及義大利價格管制等重大挑戰,我們仍達成這些亮眼成果。
Latin America sales totaled $33.7 million in the second quarter and although representing a 3 percent increase over the prior year, we experienced a number of challenges in Latin America this quarter. Latin America sales reflect a negative currency impact, lower sales volumes due to generic competition and weaker market demand. In Mexico, the market most significantly impacted, we have realigned our sales force territories and increased our sales force by about 100 sales representatives. We have also revised our targeting strategies to improve sales force efficiency and effectiveness. As pharmacies now play a major role in generic switching in Mexico, we've also begun pharmacy calls to reduce pharmacy substitution for our products. We've launched two new regional products in Mexico during this quarter, Isophase (ph), an antiacne product, and Uridol (ph), a combination muscle relaxant and analgesic.
拉丁美洲第二季銷售額合計3,370萬美元,雖較去年增加3%,但本季我們在拉丁美洲也遭遇多項挑戰。拉丁美洲銷售反映了不利的匯率影響、因學名藥競爭導致的銷量下滑,以及較疲弱的市場需求。在受影響最顯著的墨西哥,我們已重新調整銷售團隊的區域配置,並增加約100名業務代表。我們也修訂了目標客群策略,以提升銷售團隊效率與效能。由於藥局目前在墨西哥的學名藥替換中扮演重要角色,我們也開始進行藥局拜訪,以降低藥局以其他產品替代我們產品的情況。本季我們在墨西哥推出兩項新的區域性產品:Isophase(ph)(抗痘產品)以及Uridol(ph)(肌肉鬆弛劑與止痛藥的複方)。
Clearly, our core business has shown remarkable improvement this quarter, but we know that we have a lot of work ahead of us in order to build a sustainable business model that will deliver meaningful value.
顯然,我們的核心業務在本季展現了顯著改善,但我們也知道,為了建立可持續的商業模式並創造具意義的價值,前方仍有大量工作要做。
Since the beginning of this year, we've been sharing with you our thoughts on ICN's overall strategic direction. Though we are not ready to discuss the details quite yet, we are working aggressively to finalize our strategic plan for driving profitability and shareholder value. In our strategic plan, we will lay out the markets where we will focus our attention, the core brands that will drive performance on a global, regional and local level along with our sales and promotional efforts towards these brands. We will also discuss our internal and external strategies to drive future growth. In addition, really detail our master plan for delivery on our commitment to restructure our operations to a comprehensive global manufacturing and supply chain rationalization effort that we expect will significantly reduce our costs. We are also developing a plan to leverage our international buying power through global procurement initiatives.
自今年年初以來,我們一直與各位分享我們對ICN整體策略方向的想法。雖然我們尚未準備好討論細節,但我們正積極推進,以完成推動獲利能力與股東價值的策略計畫。在策略計畫中,我們將說明將聚焦的市場、在全球、區域與在地層級帶動績效的核心品牌,以及我們針對這些品牌的銷售與促銷投入。我們也將討論推動未來成長的內部與外部策略。此外,將詳細說明我們的總體計畫,以兌現我們重整營運的承諾,推動全面性的全球製造與供應鏈合理化工作,預期可大幅降低成本。我們也正在制定計畫,透過全球採購倡議來運用我們的國際採購規模優勢。
Our teams have already begun many of these efforts. We are moving forward aggressively with our growth plan and identifying key acquisition targets. We are working on 20 to 25 line extension and reformulation opportunities internally and are busy evaluating business development opportunities that will expand our portfolio. We also expect to soon be able to communicate other opportunities for significant cost savings. You already know about our previously disclosed $21 million reduction in G&A. We experienced additional improvements this quarter. We're developing plans to reduce inefficiencies and to develop additional financial benefits for the Company. We are also focused on research and development through our excellent scientific capabilities at Ribopharm and our reformulation efforts at ICN.
我們的團隊已經開始推動其中許多工作。我們正積極推進成長計畫並鎖定關鍵併購標的。我們內部正進行20到25項產品線延伸與重新配方的機會,同時也在評估可擴充產品組合的業務開發機會。我們也預期不久後即可對外溝通其他可帶來重大成本節省的機會。各位已經知道我們先前揭露的2,100萬美元G&A(一般及行政費用)削減。本季我們也有額外改善。我們正在制定計畫以降低低效率,並為公司創造更多財務效益。我們也透過Ribopharm優秀的科學能力以及ICN的重新配方工作,持續聚焦於研發。
Now Bary will provide you with a detailed review of our financial statement. Bary?
接下來Bary將為各位詳細檢視我們的財務報表。Bary?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Thank you Tim and thank you everyone for joining us. You've heard a lot already regarding our improvement on the top line. I am going to focus most of my discussion on the bottom line and then discuss our cash position and the balance sheet.
謝謝你,Tim,也謝謝各位參與。各位已經聽到許多關於我們營收端改善的內容。我將把大部分重點放在獲利端,接著再談我們的現金部位與資產負債表。
We report three primary measures of bottom-line performance, net income, income from continuing operations and loss from discontinued operations. I will spend most of my time talking about income from continuing operations as that reflects our ongoing business.
我們以三項主要指標衡量獲利端表現:淨利、持續營運所得,以及停業部門損失。我將把大部分時間用於說明持續營運所得,因為那反映我們的持續性業務。
Looking straight at the income statement you can see that income from continuing operations in the second quarter totaled 17.4 million or 21 cents per diluted share compared to 50.6 million or 56 cents per diluted share a year ago. It's important to note as Rob highlighted earlier, similar to the fourth quarter, the second quarter had no nonrecurring or unusual items reflecting our return to more normalized operations. You may recall however, that last year's results were significantly affected by nonrecurring and unusual items as well as a gain reported on the Ribopharm initial public offering. Nonrecurring and unusual items in the second quarter of last year totaled 179.9 million and consisted primarily of expenses recorded as a result of the change in board and management occurring after last year's proxy contest and our strategic repositioning and expenses related to the Ribapharm IPO.
直接看損益表可以看到,第二季持續營運所得合計1,740萬美元,或稀釋後每股21美分;相較之下,去年同期為5,060萬美元,或稀釋後每股56美分。需要特別注意的是,如Rob先前所強調,與第四季類似,第二季沒有任何一次性或異常項目,反映我們回到較正常化的營運狀態。不過各位可能還記得,去年同期的結果受到一次性與異常項目以及Ribopharm首次公開發行(IPO)所認列收益的重大影響。去年第二季的一次性與異常項目合計1億7,990萬美元,主要包括因去年委託書爭奪戰後董事會與管理階層變動、策略重新定位所認列的費用,以及與Ribapharm IPO相關的費用。
In addition, we recorded a loss in the second quarter of last year of 43.3 million on the repurchase of debt related to the Ribapharm IPO. Excluding these items, income from continuing operations in the second quarter of last year was 25.9 million, a 31 cents per diluted share.
此外,我們在去年第二季因回購與 Ribapharm IPO 相關之債務而認列 4,330 萬的損失。排除這些項目後,去年第二季持續營業單位之收益為 2,590 萬,稀釋後每股 31 美分。
With respect to the second quarter, earnings were negatively impacted by the effects of fluctuations in foreign currency. On the top line, our revenues were positively impacted in the aggregate by approximately $6 million. Operating expenses were similarly impacted but to a greater extent, resulting in foreign currency having a negative impact from income from operations of $1.4 million. In addition to the impact on income from operations, foreign currency fluctuations affected other income as a result of our cash management efforts.
就第二季而言,匯率波動的影響對盈餘造成不利衝擊。在營收端,我們的收入合計約增加 600 萬美元。營業費用亦受到類似影響但幅度更大,導致外幣對營業利益造成 140 萬美元的負面影響。除對營業利益的影響外,由於我們的現金管理作為,匯率波動亦影響其他收益。
As you may recall, ICN has had the long-standing practice of preserving the economic value of our cash holdings by keeping the majority of our international cash balances in U.S. dollars. While this mitigates local economic and political risk and helps us particularly in Argentina, the results and periodic gains and losses for accounting purposes when we translate to local U.S. dollar cash assets into local currency for financial reporting purposes. When we then translate the local currency financial statement back into U.S. dollars for GAAP reporting, an equal and offsetting entry is recorded in stockholders equity. As a result, in the 2003 second quarter ICN recorded approximately 6 million of losses in other expense due to the weakening of the U.S. Dollar in relation to the Euro, Canadian dollar and Mexican Peso. In the same period last year, ICN recorded $5 million gain from similar cash balances when the U.S. Dollar was strengthening. Essentially the recent weakening of the U.S. Dollar resulted in $11 million swing from a gain to a loss for financial reporting purposes when comparing this quarter to the same period last year while on true U.S. dollar economic terms, the Company experienced no impact.
如各位所記得,ICN 長期以來的作法是,為了維持現金持有的經濟價值,將大部分國際現金餘額以美元持有。此舉可降低當地經濟與政治風險,並特別有助於我們在阿根廷的營運,但在會計上,當我們為財務報導目的將以美元計價的當地現金資產換算為當地貨幣時,會產生定期的損益。當我們再將當地貨幣財務報表換算回美元以符合 GAAP 報導時,會在股東權益中認列等額且相互抵銷的分錄。因此,2003 年第二季,因美元相對於歐元、加幣及墨西哥披索走弱,ICN 在其他費用中認列約 600 萬的損失。去年同期,當美元走強時,ICN 就相同的現金餘額認列 500 萬美元的利益。本質上,近期美元走弱使得本季與去年同期相比,在財務報導上由盈轉虧,形成 1,100 萬美元的擺動;然而以真正的美元經濟實質衡量,公司並未受到影響。
The foreign currency fluctuation in other income were eliminated from the latest quarter and the same quarter in the prior year. And the same shares used in the respective diluted EPS calculations were used, as well as the respective tax rates of 38 percent and 38 -- 37 percent. The impact to earnings per share in the second quarter of 2003 would be an increased EPS of 4 cents while in the same quarter in 2002 would experience a reduction in EPS of 3 cents. We are taking steps to mitigate the impact of foreign currency though on a prospective basis.
我們已將最近一季及前一年同季的其他收益中的外幣波動影響予以剔除。並使用各期稀釋 EPS 計算所採用的相同股數,以及各期分別為 38% 與 38%—37% 的稅率。2003 年第二季對每股盈餘的影響將使 EPS 增加 4 美分,而 2002 年同季則會使 EPS 減少 3 美分。我們正採取措施,以在未來期間降低外幣影響。
Gross margin for the quarter of 63 percent reflects a decrease when compared to 68 percent in the same period last year. The decrease is primarily due to a change in the geographic mix in sales, inefficiency in our plant manufacturing operations in certain regions and certain costs incurred to facilitate the execution of the Company's strategy related to the rationalization of the Company's global manufacturing and supply chain.
本季毛利率為 63%,較去年同期的 68% 下滑。下降主要係因銷售地理組合改變、我們在部分地區的工廠製造作業效率不彰,以及為推動公司策略(包括精簡公司全球製造與供應鏈)而發生的部分成本。
Selling expense in the current quarter increased over the same period last year resulting in an increase in sales. G&A expenses were lower in the current quarter versus the same period last year reflecting our continued efforts to maintain strict control of overhead costs.
本季銷售費用較去年同期增加,反映銷售成長所致。本季一般及管理費用(G&A)較去年同期降低,顯示我們持續致力於嚴格控管間接費用。
ICN recorded a loss from discontinued operations in June 2003 quarter of 2.6 million compared to a loss of 18.2 million in the same quarter last year. Included in income this quarter was a loss of $6.6 million, net of related tax benefits on the sale of our Russian operations and the research products and diagnostic division of our ICN Biomedicals. Prior period amounts have been reclassified to properly reflect the discontinued operations.
ICN 在 2003 年 6 月當季認列停業單位損失 260 萬,較去年同季 1,820 萬的損失為低。本季收益中包含出售俄羅斯營運以及 ICN Biomedicals 之研究產品與診斷事業部所產生的 660 萬美元損失(扣除相關稅務利益後)。前期金額已重新分類,以適當反映停業單位。
I must note the remaining businesses to be divested include the Dissymmetry (ph) division of Biomedicals and our manufacturing operations in the Czech Republic and Hungary. The net book value of these businesses net of related tax amounts and I must note accumulated translation, totaled $25 million at June 30. Without accumulated translation, the amount is as reported on the financials in the attachments to the earnings release is 29 million. We continue to receive strong interest in these businesses and remain on track to complete their disposition before the end of this year.
我必須指出,尚待處分的剩餘業務包括 Biomedicals 的 Dissymmetry(音)事業部,以及我們在捷克共和國與匈牙利的製造營運。截至 6 月 30 日,這些業務的淨帳面價值(扣除相關稅額,並且我必須指出包含累積換算調整)合計為 2,500 萬美元。若不含累積換算調整,則如同財報(隨盈餘新聞稿附件)所揭露之金額為 2,900 萬美元。我們持續收到對這些業務的高度興趣,並仍按計畫在今年底前完成處分。
Cash at June 30 totaled 402.3 million. Let me put this number in perspective. One year ago, our cash balance was 288 million. At the end of 2002, it was down to 245 million. Just one quarter ago, cash was 302 million. For the balance of 402 million at June 30 represents a significant increase than last year and is nearly 100 million higher than reported last quarter. Our divestiture activity so far this year has added 55 million in cash and we believe our cash on hand therefore, is sufficient to fund our ongoing operations for the foreseeable future even after funding the acquisition of the 20 percent interest in Ribapharm held by third parties.
截至 6 月 30 日,現金合計為 402.3 百萬。我來把這個數字放在脈絡中說明。一年前,我們的現金餘額為 288 百萬。2002 年底降至 245 百萬。就在上一季,現金為 302 百萬。因此,6 月 30 日的 402 百萬餘額較去年顯著增加,且較上季報告數高出近 100 百萬。今年迄今我們的資產處分活動已增加 5,500 萬現金,我們因此相信手上現金足以在可預見的未來支應持續營運所需,即使在支付收購第三方持有之 Ribapharm 20% 權益之資金後亦然。
I want to conclude my remarks with a few brief words about our past guidance. I remind you that the previous guidance we gave of $1.20 to $1.25 per share for 2003 included an assumption that Ribapharm's royalty revenue would be consistent with those reported in the previous year. As Rob mentioned at the start of our call, recent events in the hepatitis C marketplace, the summary judgment position from the lower court in our patent litigation last month, has caused us to step back and question past assumptions on Ribapharm royalty revenues in 2003. In light of these uncertainties about the royalty stream, we are no longer comfortable with these assumptions. As we gain more clarity, we ought to have more to share with you later this year we hope to have more to share with you later this year. We believe however, that our specialty pharmaceuticals business remains on track and we expect to meet or exceed our expectations for this business.
我想以幾句話簡要總結我們先前的財測指引。提醒各位,我們先前對 2003 年每股 1.20 至 1.25 美元的指引,包含一項假設:Ribapharm 的權利金收入將與前一年所報告的水準一致。如 Rob 在電話會議一開始提到的,近期 C 型肝炎市場的事件,以及我們上月專利訴訟中下級法院的簡易判決立場,使我們必須退一步重新檢視 2003 年 Ribapharm 權利金收入的既有假設。鑑於權利金來源存在這些不確定性,我們已不再對這些假設感到安心。隨著情況更為明朗,我們應可在今年稍晚與各位分享更多資訊,我們希望能在今年稍晚與各位分享更多資訊。然而,我們相信我們的專科藥品業務仍按計畫推進,並預期可達成或超越我們對該業務的期望。
With that, I will turn the call back to Rob for closing remarks.
接下來,我把電話交回 Rob 作結語。
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
Thank you Bary and thank you Tim. As you heard this morning, we continue to execute on a number of fronts. Our specialty pharmaceutical business has shown remarkable improvement and is beginning to gain momentum. Clearly, we have a lot of work ahead of us but we also have a lot of opportunities. We believe ICN is on the right path toward sustainable growth.
謝謝你,Bary,也謝謝你,Tim。如各位今早所聽到的,我們持續在多個面向推進執行。我們的專科藥品業務已展現顯著改善,並開始累積動能。很明顯,我們前方仍有大量工作要做,但同時也有許多機會。我們相信 ICN 正走在通往可持續成長的正確道路上。
We also continue to make excellent progress in our strategic repositioning efforts. We are barely halfway through the year and our teams have been able to divest our most challenging operations and to do so well ahead of schedule. The interest level in our remaining divestitures operations is very high. We now are confident we will wrap up our divestiture activities by the end of the year.
我們在策略性重新定位的工作上也持續取得極佳進展。今年才剛過一半,我們的團隊就已能處分最具挑戰性的營運,且進度大幅超前。市場對我們其餘待處分營運的興趣非常高。我們現在有信心能在年底前完成處分活動。
While the Ribapharm royalties represent a near-term challenge in the U.S., our focus is on the specialty pharmaceutical business. We have a number of initiatives now in the final stages of development to improve this business. We hope to share these with you soon. We're managing our business toward long-term growth and shareholder value and we hope to share our confidence and excitement with you about the future.
雖然 Ribapharm 權利金在美國短期內帶來挑戰,我們的重點仍放在專科藥品業務。我們目前有多項計畫已進入最後開發階段,以改善此業務。我們希望很快能與各位分享。我們正以長期成長與股東價值為目標來經營公司,也希望能與各位分享我們對未來的信心與期待。
We have all seen the developments in our tender offer for Ribapharm including the press release issued yesterday morning regarding the amendment and extension of our offer. We are obviously pleased that we have reached an agreement with the Ribapharm board with regard to eliminating the rights plan. Because the tender offer is ongoing and subject to continued litigation, our ability to answer questions on the call today may be somewhat constrained.
我們都已看到我們對 Ribapharm 的公開收購要約(tender offer)的最新進展,包括昨天早上發布、關於修訂與延長要約的新聞稿。我們顯然很高興已與 Ribapharm 董事會就取消權利計畫達成協議。由於公開收購仍在進行且仍受持續訴訟影響,我們今天在電話會議上回答問題的能力可能會受到一些限制。
This has been a challenging time for all concerned at Ribapharm. But I want to take this opportunity to acknowledge the high respect and admiration we have for the scientists and employees of Ribapharm and the extraordinary work that they have done and continue to do, throughout this process.
這段時間對 Ribapharm 所有相關人士而言都相當艱難。但我想藉此機會表達,我們對 Ribapharm 的科學家與員工懷有高度敬意與欽佩,並肯定他們在整個過程中所完成且持續進行的卓越工作。
Thank you for your time today. We would now like to open up the call to questions. Operator, may we have the first question please?
感謝各位今天撥冗參與。我們現在想開放電話會議進入提問。接線員,請問可以先請第一位提問者嗎?
Operator
Operator
Please limit yourself to one question at a time. (CALLER INSTRUCTIONS) David Hoon (ph) of Advent.
請一次只提一個問題。(來電者指示)Advent 的 David Hoon(音)。
David Hoon - Analyst
David Hoon - Analyst
Hi. Can you tell me what capital expenditure was for the quarter and also what cash from operations was?
嗨。可以告訴我本季的資本支出是多少,以及營運活動產生的現金是多少嗎?
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
Phil Loburg, Treasurer?
財務主管 Phil Loburg?
Phil Loburg - Treasurer
Phil Loburg - Treasurer
Yes. Cash was running in the 20s for the year and was approximately 3 million for the quarter and operating cash flow we will have with our 10-Q filing, Dave. You can get EBITDA off our table (inaudible).
是的。今年現金大約落在 2,000 多萬的水準,本季約為 300 萬;至於營運現金流,Dave,我們會在提交 10-Q 時一併提供。你可以從我們的表格中取得 EBITDA(聽不清楚)。
Operator
Operator
Tony Fineli of Sandspoint Partners (ph).
Sandspoint Partners 的 Tony Fineli(音)。
Tony Fineli - Analyst
Tony Fineli - Analyst
Yes hi. I am wondering if you could, given the patent situation with Ribapharm, kind of go through the logic for purchasing it back rather than just sort of letting it go away?
是的,嗨。我想請問,考量 Ribapharm 的專利情況,你們是否可以說明一下,為什麼選擇把它買回來,而不是就讓它淡出?
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
This is Rob, Tony. Our view is that the interest and focus there on Ribapharm is primarily in the future, the R&D capability within the Company and the scientific personnel and what's in the pipeline in the laboratory. The royalty stream was always not necessarily the strong part of that -- looking at that. It's always been something that gives us an eye toward the future and we think that future has strong potential but obviously, for much of this discussion, there are some differences of value on that subject but we think at this price, it is still very much worth doing.
Tony,我是 Rob。我們的看法是,市場對 Ribapharm 的興趣與焦點主要在未來:公司內部的研發能力、科學人員,以及實驗室研發管線中的項目。權利金收入一直都不一定是其中最強的部分——就我們的評估而言。它一直是讓我們能著眼未來的一項資產;我們認為那個未來具有很強的潛力,但顯然在本次討論中,對其價值仍存在一些分歧。不過我們認為以這個價格來看,仍非常值得進行。
Operator
Operator
Dan Lewchanski (ph) of Merrill Lynch.
Merrill Lynch 的 Dan Lewchanski(音)。
Dan Lewchanski - Analyst
Dan Lewchanski - Analyst
Yes. I was curious about the RNA acquisition, why you would choose to use the cash rather than use equity as some of the other companies in your industry have done, do a stock swap? What your thoughts on that were?
是的。我對 RNA 的收購有點好奇:為什麼你們選擇用現金,而不是像同業其他公司那樣用股權、做換股交易?你們對此的想法是什麼?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
This is Bary Bailey. We have had a number of discussions with both ICN and RNA shareholders on this topic. As you know from a cash standpoint, the returns in the market are not that great. When we look at the relative return on investment and what we as management and board, view as the value of our equity we felt that was the most appropriate currency to use for the acquisition.
我是 Bary Bailey。我們就這個議題與 ICN 以及 RNA 的股東進行過多次討論。如你所知,就現金而言,市場上的報酬並不高。當我們比較投資報酬,並考量管理團隊與董事會對我們股權價值的看法時,我們認為以股權作為收購對價是最合適的。
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
I would add we have a growing confidence in the specialty pharmaceuticals ability to generate cash, as well. And frankly, we think, while we have no specific plan, this is certainly only the first step in our growth plan. We want to save our equity for future possibilities.
我再補充一點:我們也愈來愈有信心,專科製藥業務具備產生現金的能力。坦白說,雖然我們沒有具體計畫,但這肯定只是我們成長計畫的第一步。我們希望把股權保留給未來的可能機會。
Operator
Operator
Cliff Tanaker with ITrust Capital (ph).
ITrust Capital 的 Cliff Tanaker(音)。
Cliff Tanaker - Analyst
Cliff Tanaker - Analyst
Yes, good morning.
是的,早安。
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
Good morning.
早安。
Cliff Tanaker - Analyst
Cliff Tanaker - Analyst
I wanted to ask you at the end of the second quarter, what was the total of the assets of discontinued operations? Was that 29 million?
我想請問,在第二季末,停業部門的資產總額是多少?是 2,900 萬嗎?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
This is Bary again. Yes, it reflects 29 million but that number does not include the impact of the accumulated transition that is over on in the equity section. That's why I gave you the net number as 25 million, when you take that into account. Compared to what was reported in the first quarter where we had about 148 million, we sold the Russian business for 55 million; we sold the diagnostics and research business in our Biomedicals. We reflected a tax benefit that is now up in the regular set of the financials instead of down in discontinued operations, so that carries some of that difference from what was in the first quarter.
我又是 Bary。是的,帳面反映為 2,900 萬,但該數字不包含在權益部分所列的累積轉換影響。因此我才在把那部分納入後,給你淨額 2,500 萬。相較第一季我們約有 1.48 億的報告數字,我們以 5,500 萬出售了俄羅斯業務;也出售了生物醫藥(Biomedicals)中的診斷與研究業務。我們也反映了一項稅務利益,現在已移到一般財務報表中,而不是列在停業部門,因此也造成與第一季數字之間的部分差異。
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
If I could underscore, one of the reasons the numbers on the discontinued operations at this particular -- at the end of this quarter look a little different is because of what's happened in our Biomedicals sales. The Biomedicals business was comprised of three pieces, research products, diagnostics and dysymmetry. Diagnostics and research products were the weaker elements of that business by far, dysymmetry being the jewel in that package but unfortunately, those two businesses were on the books at a higher value. So we now have less to sell than most -- the piece of that Biomedicals business that is likely to bring us the finest return.
我想強調一下,為什麼本季末停業部門的數字看起來有些不同,其中一個原因是我們生物醫藥業務出售所造成的影響。生物醫藥業務由三個部分組成:研究產品、診斷,以及 dysymmetry。其中診斷與研究產品是該業務中明顯較弱的部分;dysymmetry 則是整個組合中的明珠,但不幸的是,那兩項業務在帳上記錄的價值較高。因此我們現在可出售的部分比以前少——而生物醫藥業務中最可能為我們帶來最佳報酬的那一塊仍在。
Operator
Operator
(CALLER INSTRUCTIONS). David Hoon of Advent.
(來電者指示)。Advent 的 David Hoon。
David Hoon - Analyst
David Hoon - Analyst
Could you comment on your dividend policy and also, if you have any plans for restructuring your debt?
你們可以談談股利政策嗎?另外,你們是否有任何重整債務的計畫?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
This is Bary again. We have a long-standing policy of paying dividends. We have not changed the policy. The Board has not. I have not heard any plans to do so for the near future.
我又是 Bary。我們長期以來一直有發放股利的政策。我們沒有改變這項政策。董事會也沒有。我沒有聽到近期有任何要改變的計畫。
Relative to restructuring debt, as you are aware, that is a convertible. The conversion feature is somewhat out of the money, I will say, and the yield on it on a relative basis if you exclude the conversion feature, is not bad. We are obviously though cognizant of what's going on in the marketplace and the relative cost of other opportunities and so, we are looking at those but we don't have any formal plans at this time.
至於債務重整,如你所知,那是一筆可轉換債。我可以說其轉換條件目前有點處於價外;若排除轉換權的影響,從相對角度看其殖利率並不差。不過我們當然也注意到市場上正在發生的情況,以及其他機會的相對成本,因此我們正在評估,但目前沒有任何正式計畫。
David Hoon - Analyst
David Hoon - Analyst
Thank you.
謝謝。
Operator
Operator
Steve Forrest of Milton Partners (ph).
Milton Partners 的 Steve Forrest(音)。
Steve Forrest - Analyst
Steve Forrest - Analyst
It's actually Mike Honeggar (ph). I was wondering on the RNA acquisition, could you explain to us a little more the significance of raising the minimum condition to 2/3?
其實我是 Mike Honeggar(音)。我想請問關於 RNA 的收購,你們能否多說明一下,把最低條件提高到 2/3 的重要性?
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
Is it Mike?
是 Mike 嗎?
Mike Honeggar - Analyst
Mike Honeggar - Analyst
Yes.
是的。
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
Mike, this is Rob. There's not much to explain. It was an element insisted upon by the Ribapharm board. It was an element of negotiation.
Mike,我是 Rob。這部分沒有太多可解釋的。這是 Ribapharm 董事會堅持的條件之一。也是談判的一個要素。
Operator
Operator
Stephen Long of Cafe Capital Financial (ph).
Cafe Capital Financial 的 Stephen Long(音)。
Stephen Long - Analyst
Stephen Long - Analyst
Hi good morning. Thanks for taking the question. The first question is on the guidance, are you ready to give a minimum range at this time?
嗨,早安。謝謝讓我提問。第一個問題關於財測指引:你們現在準備好提供一個最低區間了嗎?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
This is Bary. No. As we mentioned in the prior discussion, we will be coming back to shareholders in the later part of this year as we get more information but we are very positive about our prospects on the specialty pharmaceutical business as we move forward.
我是 Bary。還沒有。如同我們在先前討論中提到的,隨著我們取得更多資訊,我們會在今年稍晚回來向股東說明;但就我們往前推進而言,我們對專科製藥業務的前景非常正面。
Operator
Operator
Dan Lewchanski of Merrill Lynch.
Merrill Lynch 的 Dan Lewchanski。
Dan Lewchanski - Analyst
Dan Lewchanski - Analyst
I wondered if you could illuminate a little bit more on your mentioning of acquisition of line extensions and just sort of in a general way, what your plans are? Thank you.
我想請你們再多說明一下,你們提到的收購「產品線延伸」這件事;以及更概括地說,你們的計畫是什麼?謝謝。
Tim Tyson - President and COO
Tim Tyson - President and COO
Okay, this is Tim Tyson. Thank you Dan for the question. Our growth strategy is to focus on the major markets in the world, the top 10 that represent about 85 percent of the worldwide market and a couple of key products and to supplement those with lifecycle management activity for reformulations and line extensions of products that we believe there is opportunity to influence and to grow. We are also looking for opportunities to add to our portfolio through acquisition of products that have some synergy with our key therapeutic areas in the specialty pharmaceutical business to be able to accelerate our growth.
好的,我是 Tim Tyson。Dan,謝謝你的問題。我們的成長策略是聚焦於全球主要市場,也就是前 10 大市場,約占全球市場的 85%,並聚焦於幾項關鍵產品;同時透過生命週期管理活動來補強,包括我們認為有機會影響並推動成長的產品再配方與產品線延伸。我們也在尋找機會,透過收購與我們專科製藥業務關鍵治療領域具有協同效益的產品,來擴充產品組合,以加速成長。
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
I would add Dan, that ICN had not historically had what you would call an ongoing lifecycle management program so that we have a number of older drugs, more mature drugs that should have been -- had reformulation efforts started at an earlier point in their lifecycle. What Wes Wheeler, the head of our global marketing program in North America and Tim have done in these few short months is begun the catch up phase of starting reformulations on the most attractive opportunities within those existing products and put in place a process that will begin to initiate for our future earlier reformulation and line extension activities in the lifecycle of our less mature drugs, as well. So we are basically doing a catch up piece of work now which will have some nice benefit for us as we get into later in the year and next year and we are putting a process in place much like our attitude on how we handle inventory so that we don't ever find ourselves in this sort of position again. But we should expect that because we've been behind and not had the advantage of this kind of activity in the past, somewhere in the months ahead, we are going to get somewhat of a double bump from the catch up and from now having in place an ongoing program in lifecycle management.
我想補充一下,Dan,ICN 過去在歷史上並沒有你所謂的持續性產品生命週期管理(lifecycle management)計畫,因此我們有不少較舊、較成熟的藥品,本應該在其生命週期較早階段就開始進行重新配方(reformulation)的工作。在這短短幾個月裡,Wes Wheeler(我們北美全球行銷計畫的負責人)以及 Tim 所做的,是開始進入追趕階段:針對現有產品中最具吸引力的機會啟動重新配方,並建立一套流程,讓我們未來也能在較不成熟藥品的生命週期更早期就啟動重新配方與產品線延伸(line extension)活動。所以我們現在基本上是在做一段追趕性的工作,這將在今年稍晚以及明年為我們帶來不錯的效益;同時我們也建立了一套流程,這點很像我們處理庫存的態度,確保不會再讓自己陷入這種處境。但我們應該預期,由於我們過去落後、也沒有享受到這類活動的優勢,在接下來幾個月內,我們會因追趕效應以及現在已建立的持續性生命週期管理計畫而獲得某種程度的「雙重推升」。
Operator
Operator
(CALLER INSTRUCTIONS). Cliff Tanaker with ITrust Capital.
(來電者指示)。ITrust Capital 的 Cliff Tanaker。
Cliff Tanaker - Analyst
Cliff Tanaker - Analyst
Yes, I just had a second question. I wanted to know, you mentioned that the growth in the North American pharmaceuticals business in the second quarter was driven by increased kind of selling and marketing efforts and I'm wondering if you could kind of outline what is your marketing unit look like in North America as well as what effort in the second quarter helped to increase the sales?
是的,我還有第二個問題。我想了解,你提到第二季北美製藥業務的成長是由加強銷售與行銷投入所帶動;我想請你概述一下北美的行銷單位大概是什麼樣子,以及第二季有哪些努力有助於提升銷售?
Tim Tyson - President and COO
Tim Tyson - President and COO
This is Tim Tyson. There are a couple of things we are focused on in North America. Number one, we've hired a professional that understands and has significant experience in the marketplace, Wes Wheeler, President of the organization, and he supplemented his team with people who have good knowledge and experience. We focused on the products where there is opportunity. I mentioned Efudex, which is the market leader in actinic keratosis and Kinerase. We have done some lifecycle management activity and we've refocused our sales force. We've totally rebuilt our promotional platform and our targeting activity. We are looking at the opportunities for influencing the marketplace in the managed care sector and build a team around that and the third party payers and we've also revised our sales force. We let 20 people go and hired 20 additional or new people to improve the competency and we added to our sales force after a detailed size and structure analysis to be able to influence the marketplace. All of those activities are paying off and we're seeing some great benefit and the last thing that has made a major improvement is developing good relationships with the 3 major wholesalers to manage the wholesale activities in the marketplace.
我是 Tim Tyson。我們在北美主要聚焦幾件事。第一,我們聘請了一位了解市場且具備豐富市場經驗的專業人士——Wes Wheeler,擔任該組織的總裁;他也以具備良好知識與經驗的人才補強了團隊。我們把重點放在有機會的產品上。我提到過 Efudex,它是日光性角化症(actinic keratosis)的市場領導品牌,以及 Kinerase。我們已進行一些生命週期管理活動,並重新聚焦我們的銷售團隊。我們徹底重建了促銷平台與目標客群鎖定(targeting)活動。我們也在尋找影響市場的機會,特別是在管理式醫療(managed care)領域,並圍繞該領域與第三方付款方建立團隊;同時也調整了我們的銷售隊伍。我們讓 20 位人員離開,並另外聘用 20 位新增或新進人員以提升能力;在完成詳細的規模與組織結構分析後,我們也擴編了銷售隊伍,以便能影響市場。上述所有活動都正在發揮效果,我們看到很大的效益;最後一項帶來重大改善的是,與三大主要批發商建立良好關係,以管理市場中的批發活動。
Operator
Operator
Michael Stanski of Trudor Investment (ph).
Trudor Investment(音) 的 Michael Stanski。
Michael Stanski - Analyst
Michael Stanski - Analyst
Two questions. Tim, could you talk about where you are as far as far as your review of the manufacturing facilities? Should we see any write-offs in the future? How comfortable do you feel in reviewing that? And second, do you feel the Company is at a point where it can handle from a marketing standpoint, end licensing any products and where you stand as far as timing on that?
兩個問題。Tim,你能談談你們對製造設施的檢視目前進展到哪個階段嗎?未來我們是否會看到任何減記(write-offs)?你對於檢視結果的把握程度如何?第二,你認為公司在行銷面是否已到能夠承接引進授權(in-licensing)產品的階段?在時程上目前進展如何?
Tim Tyson - President and COO
Tim Tyson - President and COO
The first question Michael, thanks for the question. We have gone through some significant activities in the manufacturing analysis and we are nearing a position where we will be making a proposal, making some decisions and we committed to communicating by the end of the year that strategy and our thoughts about the implications to the business and I am comfortable now that we will be able to communicate that earlier than previously indicated to you and that we are feeling very good and we have great opportunity there and I think you'll see when we are able to talk about the detail, that we will be aggressive at challenging that operation and improving our efficiency.
第一個問題,Michael,謝謝你的提問。我們已在製造分析上進行了一些重大工作,目前接近將提出方案、做出一些決策的階段;我們也承諾會在年底前對外溝通該策略以及我們對其對業務影響的看法。我現在有信心,我們能比先前向各位所表示的更早進行溝通;而且我們感覺非常好,這裡有很大的機會。我想當我們能談到細節時,你會看到我們會積極挑戰該營運並提升效率。
The second part of your question, the write-off question is totally dependent upon decisions that we will take and we will communicate implications of the manufacturing rationalization when we communicate that plan.
你問題的第二部分,也就是減記的問題,完全取決於我們將做出的決策;當我們溝通製造合理化(rationalization)計畫時,也會一併說明其影響。
Michael Stanski - Analyst
Michael Stanski - Analyst
Tim, will those be cash write-offs?
Tim,那些會是現金減記嗎?
Tim Tyson - President and COO
Tim Tyson - President and COO
I'm sorry Michael?
抱歉,Michael?
Michael Stanski - Analyst
Michael Stanski - Analyst
Will those write-offs be cash Bary, or book write-offs?
那些減記會是現金性的,Bary,還是帳面減記?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
No, as we have mentioned, as we have met with a number of you all, we are expecting if we go through a rationalization efforts, there's likely to be book adjustments to the assets. We are expecting those won't be cash write-offs.
不會。正如我們先前提到、也與在座多位會面時所說,如果我們進行合理化工作,很可能會對資產做帳面調整。我們預期那不會是現金減記。
Michael Stanski - Analyst
Michael Stanski - Analyst
The second question regarding the ability and timing on end licensing?
第二個問題是關於引進授權(in-licensing)的能力與時程?
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
Michael, as you know, our promotional activities and the people that are focused on those are looking for opportunities for new messages and new opportunities. We are absolutely ready for and able to take on acquisition products and to bring them to the marketplace and focus on driving some growth.
Michael,如你所知,我們的促銷活動以及專注於這些工作的團隊,正在尋找新的訊息與新的機會。我們絕對已準備好、也有能力承接併購而來的產品,將其推向市場並專注於帶動成長。
Michael Stanski - Analyst
Michael Stanski - Analyst
Thank you.
謝謝。
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
Michael, I am going to add while we are not prepared today to talk specifically about the manufacturing rationalization program, we will get back to you in the months ahead about that. I want to leave you with a clear impression that what we are looking at is a dramatic restructuring of this Company. We are not going to be playing around the edges with this thing. The divestiture program is going to be a significant assist in eliminating the complexity and volume of our manufacturing facilities around the world. But even after that is done, the plan that Tim is working on will dramatically change the profile of this company and our manufacturing and supply chain operations, so we are looking at something that will have a very significant effect we believe, on our cost of goods sold.
Michael,我補充一下:雖然我們今天還未準備好具體談製造合理化計畫,但在接下來幾個月我們會再回覆你。我想讓你清楚知道,我們正在評估的是對公司進行大幅度的重整。我們不會只是在邊邊角角做文章。資產剝離(divestiture)計畫將大幅協助我們降低全球製造設施的複雜度與規模。但即使完成之後,Tim 正在推動的計畫也將大幅改變公司的樣貌,以及我們的製造與供應鏈營運;因此我們認為,這將對我們的銷貨成本(cost of goods sold)產生非常顯著的影響。
Operator
Operator
At this time, there are no further questions. I will now turn the call back over to Mr. Robert O'Leary.
目前沒有其他問題。我現在把電話交回給 Robert O'Leary 先生。
Rob O'Leary - Chairman and CEO
Rob O'Leary - Chairman and CEO
Thank you all very much for being with us this morning. It's a lot of fun to report to you on some of the fruits of the efforts that have been going on for, particularly these last six months and the setup of those activities in the months before that. There's no question that we've got the right team in place here and that this company is about ready to take off. I hope you see that foreshadowed in the second quarter results and we expect to drive forward in the remainder of the year and finish '04 -- finish '03 on a high note and take us into a strong '04. Thank you all for your participation today. We look forward to talking to you in the near future.
非常感謝各位今天早上與我們一同參與。能向各位報告這些努力所結出的成果令人非常愉快,尤其是過去六個月的努力,以及在那之前幾個月對相關活動的建置。毫無疑問,我們已在這裡建立了正確的團隊,而公司也已準備好起飛。我希望你們已在第二季的結果中看到一些端倪;我們預期在今年剩餘時間持續推進,並以高點結束 2003 年('03),帶領我們進入強勁的 2004 年('04)。感謝各位今天的參與。我們期待在不久的將來再與各位交流。
Operator
Operator
(CALLER INSTRUCTIONS).
(來電者指示)。